Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 4—April 2011

Dispatch

Hepatitis A Virus Vaccine Escape Variants and Potential New Serotype Emergence

Unai Pérez-Sautu1, M. Isabel Costafreda1, Joan Caylà, Cecilia Tortajada, Josep Lite, Albert Bosch, and Rosa M. PintóComments to Author 
Author affiliations: Author affiliations: University of Barcelona, Barcelona, Spain (U. Pérez-Sautu, M.I. Costafreda, A. Bosch, R.M. Pintó); Public Health Agency of Barcelona, Barcelona (J. Caylà, C. Tortajada); CatLab, Viladecavalls, Spain (J. Lite)

Main Article

Figure 1

Hepatis A virus protomer model (11; refined by Ming Luo, University of Alabama, Birmingham, AL, USA), which includes the locations of all of the substituted residues in viral protein 1 detected in the isolated variants during 2005–2009. A) Front view of the external surface. B) Lateral view. C) View of 2 adjacent protomers, showing the close contact of residues 1171 and 1280. Red, residues forming the immunodominant site; yellow, residues substituted in monoclonal antibody–resistant mutants C6 (

Figure 1. Hepatis A virus protomer model (11; refined by Ming Luo, University of Alabama, Birmingham, AL, USA), which includes the locations of all of the substituted residues in viral protein 1 detected in the isolated variants during 2005–2009. A) Front view of the external surface. B) Lateral view. C) View of 2 adjacent protomers, showing the close contact of residues 1171 and 1280. Red, residues forming the immunodominant site; yellow, residues substituted in monoclonal antibody–resistant mutants C6 (W1170C) and P29 (A1187P); green, residues substituted in the identified natural variants. The amino acid substitution V1171A detected in 1 variant is shown in red because this residue belongs to the immunodominant site.

Main Article

1These authors contributed equally to this article.

TOP